Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBritish American Tobacco Regulatory News (BATS)

Share Price Information for British American Tobacco (BATS)

Share Price is delayed by 15 minutes
Get Live Data
4,404.00    84.00 (1.94%)
Bid:
4,423.00
Ask:
4,425.00
Spread: 2.00 (0.045%)
Market Cap: £95.19b
BATS Live PriceLast checked at - London Stock Exchange

Intraday British American Tobacco Share Chart

Pricing Notes Offering

19 Sep 2025 09:40

RNS Number : 0593A
British American Tobacco PLC
19 September 2025
 

19 September 2025

British American Tobacco Announces Pricing of $750,000,000 Notes Offering

British American Tobacco p.l.c. ("BAT") today announces that B.A.T Capital Corporation (the "Issuer"), a wholly owned subsidiary of BAT, has priced an offering of $750,000,000 aggregate principal amount of 4.625% Notes due 2033 (the "Notes").

The Notes will be fully and unconditionally guaranteed on a senior and unsecured and joint and several basis by BAT, B.A.T. International Finance p.l.c. ("BATIF"), B.A.T. Netherlands Finance B.V. ("BATNF") and, unless its guarantee is released in accordance with the relevant indenture, Reynolds American Inc. ("RAI").

The issuance of the Notes is expected to close on 22 September 2025, subject to customary closing conditions.

BAT intends to use the net proceeds of the offering of the Notes for general corporate purposes, including the potential repayment of existing indebtedness.

Barclays Capital Inc., BBVA Securities Inc., Lloyds Securities Inc. and Santander US Capital Markets LLC are acting as joint book-running managers for the offering. Bank of China Limited, London Branch, Commerz Markets LLC and SMBC Nikko Securities America, Inc. are acting as bookrunners.

The offering of the Notes will be made under BAT's existing effective shelf registration statement on file with the U.S. Securities and Exchange Commission (the "SEC"), which is available online at www.sec.gov. A preliminary prospectus supplement and an accompanying prospectus describing the terms of the offering and other information relating to the Issuer, BATIF, BAT, BATNF and RAI have been filed with the SEC. The shelf registration statement, the preliminary prospectus supplement and the accompanying prospectus may be obtained, free of charge, by contacting Barclays Capital Inc. toll-free at 1-888-603-5847, BBVA Securities Inc. toll-free at 1-800-422-8692, Lloyds Securities Inc. at 1-212-930-5039 and Santander US Capital Markets LLC toll-free at 1-855-403-3636.

The preliminary prospectus supplement is also available at:

424B2 (sec.gov)

The shelf registration statement is also available at:

F-3ASR (sec.gov)

This communication shall not constitute an offer to sell nor a solicitation of an offer to buy the Notes. This offering is being made only pursuant to the Form F-3 registration statement, the prospectus supplement and the accompanying prospectus and only to such persons and in such jurisdictions as is permitted under applicable law.

About BAT

BAT is a leading global multi-category consumer goods business. Underpinned by world-leading science and research and development, our purpose is to create A Better Tomorrow™ by Building a Smokeless World.

Central to achieving this is the concept of Tobacco Harm Reduction (THR) - the switching of smokers, who would otherwise continue to smoke, from risky forms of combustible tobacco products like cigarettes, to lower risk profile smokeless tobacco and nicotine products*. This is outlined further in Omni™, an evidence-based manifesto for change, which captures BAT's commitment and progress on THR.

BAT's aim is to have 50 million adult consumers of its smokeless products* by 2030 and generate 50% of its revenue from these products by 2035.

* Based on the weight of evidence and assuming a complete switch from cigarette smoking. These products are not risk free and are addictive.  Our products as sold in the US, including Vuse, Velo, Grizzly, Kodiak, and Camel Snus, are subject to Food and Drug Administration (the "FDA") regulation and no reduced-risk claims will be made as to these products without FDA clearance.

Forward-Looking Statements

This announcement contains certain forward-looking statements, including "forward-looking" statements made within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. These statements are often, but not always, made through the use of words or phrases such as "believe," "anticipate," "could," "may," "would," "should," "intend," "plan," "potential," "predict," "will," "expect," "estimate," "project," "positioned," "strategy," "outlook", "target" and similar expressions. These include statements regarding our intentions, beliefs or current expectations concerning, amongst other things, the offering of the Notes, our customer target ambition, our smokeless products revenue targets and our sustainability targets.

All such forward-looking statements involve estimates and assumptions that are subject to risks, uncertainties and other factors. It is believed that the expectations reflected in this announcement are reasonable but they may be affected by a wide range of variables that could cause actual results to differ materially from those currently anticipated. The forward-looking statements should be read in conjunction with the other cautionary statements that are included in BAT's filings with the SEC, including BAT's 2024 Annual Report on Form 20-F and other reports furnished on Form 6-K.

The forward-looking statements in this announcement reflect knowledge and information available and BAT undertakes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise. Readers are cautioned not to place undue reliance on such forward-looking statements.

Additional information concerning these and other factors can be found in BAT's filings with the SEC, including the Annual Report on Form 20-F filed on 14 February 2025 and Current Reports on Form 6-K, which may be obtained free of charge at the SEC's website, www.sec.gov.

Prohibition of Sales to U.K. Retail Investors

The Notes are not intended to be offered, sold or otherwise made available to and should not be offered, sold or otherwise made available to any retail investor in the United Kingdom ("U.K."). For these purposes, a "retail investor" means a person who is one (or more) of: (i) a retail client, as defined in point (8) of Article 2 of Regulation (EU) No 2017/565 as it forms part of U.K. domestic law by virtue of the European Union (Withdrawal) Act 2018 (as amended, the "EUWA"); (ii) a customer within the meaning of the provisions of the Financial Services and Markets Act 2000 (as amended, the "FSMA") and any rules or regulations made under the FSMA to implement Directive (EU) 2016/97, where that customer would not qualify as a professional client, as defined in point (8) of Article 2(1) of Regulation (EU) No 600/2014 as it forms part of U.K. domestic law by virtue of the EUWA; or (iii) not a qualified investor as defined in Article 2 of Regulation (EU) 2017/1129 as it forms part of U.K. domestic law by virtue of the EUWA and the expression an "offer" includes the communication in any form and by any means of sufficient information on the terms of the offer and the Notes to be offered so as to enable an investor to decide to purchase or subscribe for the Notes.

Consequently, no key information document required by Regulation (EU) No 1286/2014 as it forms part of U.K. domestic law by virtue of the EUWA (the "UK PRIIPs Regulation") for offering or selling the Notes or otherwise making them available to retail investors in the U.K. has been prepared and therefore offering or selling the Notes or otherwise making them available to any retail investor in the U.K. may be unlawful under the UK PRIIPs Regulation.

Prohibition of Sales to EEA Retail Investors

The Notes are not intended to be offered, sold or otherwise made available to and should not be offered, sold or otherwise made available to any retail investor in the European Economic Area ("EEA"). For these purposes, a "retail investor" means a person who is one (or more) of: (i) a retail client as defined in point (11) of Article 4(1) of Directive 2014/65/EU (as amended, "MiFID II"); (ii) a customer within the meaning of Directive (EU) 2016/97, where that customer would not qualify as a professional client as defined in point (10) of Article 4(1) of MiFID II; or (iii) not a qualified investor as defined in Regulation (EU) 2017/1129 (the "Prospectus Regulation") and the expression "offer" includes the communication in any form and by any means of sufficient information on the terms of the offer and the Notes to be offered so as to enable an investor to decide to purchase or subscribe for the Notes.

Consequently, no key information document required by Regulation (EU) No 1286/2014 (as amended, the "PRIIPs Regulation") for offering or selling the Notes or otherwise making them available to retail investors in the EEA has been prepared and therefore offering or selling the Notes or otherwise making them available to any retail investor in the EEA may be unlawful under the PRIIPs Regulation.

Enquiries:

Media Centre

press_office@bat.com | @BATplc

Investor Relations

Victoria Buxton | IR_team@bat.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IODPKCBDFBKKDCD
Date   Source Headline
11th Nov 202510:30 amRNSDirector/PDMR Shareholding
11th Nov 20257:00 amRNSTransaction in Own Shares
10th Nov 20257:00 amRNSTransaction in Own Shares
7th Nov 20257:00 amRNSTransaction in Own Shares
6th Nov 20253:15 pmRNSDirector/PDMR Shareholding
6th Nov 20257:00 amRNSTransaction in Own Shares
5th Nov 20257:00 amRNSTransaction in Own Shares
4th Nov 20257:00 amRNSTransaction in Own Shares
3rd Nov 20252:45 pmRNSTotal Voting Rights
31st Oct 20252:45 pmRNSSubtantial Repurchase Event
31st Oct 20257:00 amRNSTransaction in Own Shares
30th Oct 20257:00 amRNSTransaction in Own Shares
29th Oct 20259:15 amRNSResult of Tender Offer
29th Oct 20257:00 amRNSTransaction in Own Shares
28th Oct 202512:11 pmRNSPublication of a Prospectus
28th Oct 20257:00 amRNSTransaction in Own Shares
27th Oct 20257:00 amRNSTransaction in Own Shares
24th Oct 20257:00 amRNSTransaction in Own Shares
23rd Oct 20257:00 amRNSTransaction in Own Shares
22nd Oct 20257:00 amRNSTransaction in Own Shares
21st Oct 20258:50 amRNSTender Offer
21st Oct 20257:00 amRNSTransaction in Own Shares
20th Oct 20257:00 amRNSTransaction in Own Shares
17th Oct 202510:30 amRNSHolding(s) in Company
17th Oct 20257:00 amRNSTransaction in Own Shares
16th Oct 20257:00 amRNSTransaction in Own Shares
15th Oct 20257:00 amRNSTransaction in Own Shares
14th Oct 20257:05 amRNSTransaction in Own Shares
14th Oct 20257:00 amRNSDirectorate Change
13th Oct 202510:00 amRNSHolding(s) in Company
10th Oct 20257:00 amRNSTransaction in Own Shares
9th Oct 20257:05 amRNSTransaction in Own Shares
9th Oct 20257:00 amRNSShare Buyback Programme
8th Oct 20257:00 amRNSTransaction in Own Shares
7th Oct 20257:00 amRNSTransaction in Own Shares
6th Oct 20257:00 amRNSTransaction in Own Shares
3rd Oct 20257:00 amRNSTransaction in Own Shares
2nd Oct 20253:15 pmRNSDirector/PDMR Shareholding
2nd Oct 20257:00 amRNSTransaction in Own Shares
1st Oct 202511:15 amRNSTotal Voting Rights
1st Oct 20257:00 amRNSTransaction in Own Shares
30th Sep 202510:45 amRNSHolding(s) in Company
30th Sep 20257:00 amRNSTransaction in Own Shares
29th Sep 20257:00 amRNSTransaction in Own Shares
26th Sep 20257:00 amRNSTransaction in Own Shares
25th Sep 20257:00 amRNSTransaction in Own Shares
24th Sep 20257:00 amRNSTransaction in Own Shares
23rd Sep 20257:00 amRNSTransaction in Own Shares
22nd Sep 20257:05 amRNSTransaction in Own Shares
22nd Sep 20257:00 amRNSBranch Register: Dividend Finalisation Information

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.